Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised $121 million by offering 5.8 million shares at $21, above the range of $19 to $20. Ultragenyx Pharmaceutical plans to list on the NASDAQ under the symbol RARE. Ultragenyx Pharmaceutical initially filed confidentially on 10/4/2013. J.P. Morgan and Morgan Stanley acted as joint bookrunners on the deal.
